Weber M M, Fottner C, Schmidt P, Brodowski K M, Gittner K, Lahm H, Engelhardt D, Wolf E
Medical Department II, Klinikum Grosshadern, Munich, Germany.
Endocrinology. 1999 Apr;140(4):1537-43. doi: 10.1210/endo.140.4.6660.
The influence of postnatal insulin-like growth factor II (IGF-II) overexpression on adrenal growth and function was investigated in 3-month-old male phosphoenolpyruvate carboxykinase (PEPCK) promoter human IGF-II transgenic mice, which are characterized by 4-to 6-fold elevated postnatal IGF-II serum levels. Plasma corticosterone levels of PEPCK-IGF-II transgenic mice were 2-fold higher than in age- and sex-matched controls, both in the morning (7.4 +/- 1.5 vs. 17.8 +/- 3.9 ng/ml, P < 0.01) and in the evening (33.3 +/- 6.5 vs. 65.3 +/- 12 ng/ml, P < 0.01). When PEPCK-IGF-II transgenic mice were subjected to an ACTH challenge, corticosterone levels were stimulated 6-fold, to 396 +/- 17 ng/ml after 60 min, compared with 230 +/- 24 ng/ml in the control group. In contrast to corticosterone, plasma ACTH levels were similar in transgenic and control mice, excluding an indirect effect of IGF-II at the hypothalamic or pituitary level. In vitro, the basal and ACTH-induced corticosterone production of adrenal glands from transgenic mice was higher (2-fold and 1.8-fold, respectively) than that of control organs. However, when normalized for adrenal weight, the in vitro corticosterone secretion was similar in both groups. At autopsy, adrenal weights of transgenic mice were significantly greater than those of control adrenal glands (3.3 +/- 0.2 vs. 2.0 +/- 0.2 mg, P < 0.01, n = 10). Furthermore, a local expression of human IGF-II could be demonstrated in transgenic adrenal glands by RT-PCR, whereas in normal adult mice, no adrenal expression of IGF-II was detected. Stereological investigation of adrenal glands from another set of PEPCK-IGF-II transgenic mice and controls (6-month-old males) demonstrated that the increase in adrenal weight in transgenic mice is mainly caused by a 50% increase in the number of zona fasciculata cells, whereas cell volume and zonation of transgenic adrenal glands remained unchanged. In conclusion, our data indicate that postnatal overexpression of IGF-II induces an increased adrenal weight and elevated corticosterone serum levels, presumably by a direct mitogenic effect of IGF-II on adrenocortical fasciculata cells.
在3月龄雄性磷酸烯醇丙酮酸羧激酶(PEPCK)启动子驱动的人胰岛素样生长因子II(IGF-II)转基因小鼠中,研究了出生后IGF-II过表达对肾上腺生长和功能的影响,这些小鼠的特点是出生后血清IGF-II水平升高4至6倍。PEPCK-IGF-II转基因小鼠的血浆皮质酮水平在上午(7.4±1.5对17.8±3.9 ng/ml,P<0.01)和晚上(33.3±6.5对65.3±12 ng/ml,P<0.01)均比年龄和性别匹配的对照组高2倍。当对PEPCK-IGF-II转基因小鼠进行促肾上腺皮质激素(ACTH)刺激时,皮质酮水平在60分钟后被刺激6倍,达到396±17 ng/ml,而对照组为230±24 ng/ml。与皮质酮不同,转基因小鼠和对照小鼠的血浆ACTH水平相似,排除了IGF-II在下丘脑或垂体水平的间接作用。在体外,转基因小鼠肾上腺的基础和ACTH诱导的皮质酮产生均高于对照器官(分别高2倍和1.8倍)。然而,以肾上腺重量进行标准化后,两组的体外皮质酮分泌相似。尸检时,转基因小鼠的肾上腺重量显著大于对照肾上腺(3.3±0.2对2.0±0.2 mg,P<0.01,n = 10)。此外,通过逆转录聚合酶链反应(RT-PCR)可在转基因肾上腺中证明人IGF-II的局部表达,而在正常成年小鼠中未检测到肾上腺IGF-II的表达。对另一组PEPCK-IGF-II转基因小鼠和对照小鼠(6月龄雄性)的肾上腺进行体视学研究表明,转基因小鼠肾上腺重量的增加主要是由于束状带细胞数量增加50%,而转基因肾上腺的细胞体积和分区保持不变。总之,我们的数据表明,出生后IGF-II过表达导致肾上腺重量增加和血清皮质酮水平升高,可能是由于IGF-II对肾上腺皮质束状带细胞的直接促有丝分裂作用。